Azacitidine or decitabine

Phase 2Small molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Azacitidine or decitabine is one of 64 small molecule programs targeting MDS. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MDSRecruiting

Efficacy and SafetyUnknown status

Myeloid MalignanciesRecruiting

MDSPhase 2

Recruiting

Efficacy and SafetyPreclinical

Unknown status

Myeloid MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

9 2

Rinvoq

AbbVie

Phase 3

4 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 4

Rapamune

PPrism Pharmaceuticals

Phase 3

5 5

Rilutek

AAzurity Pharmaceuticals

Phase 3

3 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Becotatug Vedotin

FFudan University

Phase 3

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

1 10

VAY736

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Recruiting

MDS

NCT07238686

Clinical

Trials by Indication[1]

Withdrawn·UUniversity of Florida·Phase 2·NCT05766514

MDS1 trial

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

Recruiting·—·Phase 2·NCT07238686·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Azacitidine or decitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azacitidine or decitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azacitidine or decitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Azacitidine or decitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Efficacy and Safety1 trial

Myeloid Malignancies1 trial

Frontline1 trial

MDS1 trial

References

Drug Info

Quick Facts

Related News